Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) - Trial NCT06221670
Access comprehensive clinical trial information for NCT06221670 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 51 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 2
Mar 20, 2024
Mar 20, 2031
Primary Outcome
3-year DFS rate
Summary
This is a prospective, open, single-center, single-arm phase II clinical study in non-small
 cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK
 fusion variants identified in the central laboratory. To evaluate the efficacy and safety of
 adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with
 high-risk factors.
Data Source
ClinicalTrials.gov
NCT06221670
Non-Device Trial